文献速递关节外科

膝关节或髋关节置换术后应使用何种镇痛药缓解疼痛?随机对照试验的系统综述与网络Meta分析

Which Analgesic Should We Use to Relieve Pain After Knee or Hip Arthroplasty? A Systematic Review and Network Meta-analysis of RCTs.
PubMed 文献 · Clin Orthop Relat Res · 2025-11-03

本网络Meta分析纳入211项随机对照试验、22972例患者,比较膝关节或髋关节置换术后155种镇痛方案的疗效与安全性。膝关节置换术后局部左布比卡因在镇痛方面似乎最有效,髋关节置换术后局部罗哌卡因联合酮咯酸和肾上腺素似乎最佳;神经阻滞左布比卡因联合右美托咪定(在监测条件下使用)在膝关节置换术后功能改善方面似乎最有效。

要点

  • 膝关节置换术后,与安慰剂相比,局部左布比卡因镇痛最有效(均数差-4.9 cm,95%可信区间-7.5至-2.2)。
  • 髋关节置换术后,与安慰剂相比,局部罗哌卡因联合酮咯酸和肾上腺素最有效(均数差-3.5 cm,95%可信区间-4.9至-2.0)。
  • 膝关节置换术后功能改善方面,神经阻滞左布比卡因联合右美托咪定(在监测条件下使用)获益最大(均数差63°,95%可信区间35°至91°)。

核心结论

  • 膝关节置换术后,局部左布比卡因似乎是镇痛最有效的选择。
  • 髋关节置换术后,局部罗哌卡因联合酮咯酸和肾上腺素似乎是最佳选择。
  • 功能改善方面,膝关节置换术后神经阻滞左布比卡因联合右美托咪定(在监测条件下使用)似乎最有效。
  • 大多数干预措施的安全性特征相似,但静脉曲马多联合甲氧氯普胺降低了恶心风险。
  • 临床医生应将上述结果与已知安全性特征及患者个体因素相结合,以指导膝关节和髋关节置换术后个体化疼痛管理。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane Library、Web of Science及参考文献列表,检索时间从建库至2023年7月6日,更新至2025年7月13日。
  • 纳入比较特定镇痛药与安慰剂或其他镇痛药的随机对照试验,要求每组至少10例参与者、术后给药、报告疼痛、功能或不良事件相关结局。
  • 共纳入211项随机对照试验,包含22972例患者(中位年龄67岁,范围43至80岁;女性比例24%至98%),涵盖5种给药途径(静脉、神经阻滞、局部浸润镇痛、口服、外用)及其组合的155种不同镇痛方案。
  • 偏倚风险采用Cochrane偏倚风险工具2.0评估(79%评为「有些担忧」,21%评为「高风险」),证据确信度采用CINeMA框架评估,评级从中等到极低。
  • 疼痛为主要结局,重点关注术后24小时疼痛;术后48小时疼痛为次要结局;优先采用运动时疼痛而非静息时疼痛。

主要发现

  • 膝关节置换术后,与安慰剂相比,局部左布比卡因镇痛最有效(均数差-4.9 cm,95%可信区间-7.5至-2.2;SUCRA 99%),超过预设最小临床重要差值-1.8 cm的概率为85%。
  • 髋关节置换术后,与安慰剂相比,局部罗哌卡因联合酮咯酸和肾上腺素最有效(均数差-3.5 cm,95%可信区间-4.9至-2.0;SUCRA 73%),达到最小临床重要差值的概率为99%。
  • 膝关节置换术后功能改善方面,与安慰剂相比,神经阻滞左布比卡因联合右美托咪定(在监测条件下使用)获益最大(均数差63°,95%可信区间35°至91°;SUCRA 88%),度数越高表示活动度越大。
  • 安全性方面,与安慰剂相比,静脉曲马多联合甲氧氯普胺降低恶心风险(OR 0.1,95%可信区间0.0至0.7),而神经阻滞布比卡因联合舒芬太尼增加恶心风险(OR 6,95%可信区间1至31)。
  • 其余不良事件在各干预措施之间未观察到其他差异。

关键数值与推荐

  • 疼痛最小临床重要差值预设为10 cm视觉模拟评分(VAS)上的-1.8 cm。
  • 疼痛数据提取采用预设层级:VAS优先,其次语言评定量表,再次数字评定量表。
  • 膝关节置换术后局部左布比卡因与安慰剂比较的均数差为-4.9 cm(95%可信区间-7.5至-2.2),SUCRA 99%。
  • 髋关节置换术后局部罗哌卡因联合酮咯酸和肾上腺素与安慰剂比较的均数差为-3.5 cm(95%可信区间-4.9至-2.0),SUCRA 73%。
  • 膝关节置换术后神经阻滞左布比卡因联合右美托咪定(在监测条件下使用)与安慰剂比较的功能改善均数差为63°(95%可信区间35°至91°),SUCRA 88%。

临床怎么用

  • 临床医生应将上述结果与已知安全性特征及患者个体因素相结合,以指导膝关节和髋关节置换术后个体化疼痛管理。

局限性

  • 79%的随机对照试验评为「有些担忧」,21%评为「高风险」偏倚风险。
  • 证据确信度评级从中等到极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective postoperative pain management after knee and hip arthroplasties offers substantial clinical benefits; however, clinicians are faced with numerous analgesic options, and therapeutic decision-making is hindered by limited comparative evidence on the relative efficacy and safety of these treatments. Previous studies were limited to pairwise comparisons and could not integrate the full spectrum of available treatments or were focused on specific routes of administration that overlooked variability among individual analgesics within and across these routes. Therefore, an analysis comparing all analgesics that have been evaluated in randomized trials for use after knee and hip arthroplasty is warranted. QUESTIONS/PURPOSES: The purpose of this study was to perform a network meta-analysis that evaluates the relative efficacy and safety of currently available analgesics administered across different routes to determine which provide the greatest benefit in terms of (1) reducing postoperative pain, (2) improving function, and (3) minimizing adverse events. Given the distinct anatomic and biomechanical features of hips and knees and their differing postoperative pain trajectories, we conducted separate analyses for each procedure. METHODS: For this network meta-analysis, we systematically searched PubMed, Embase, the Cochrane Library, Web of Science, and reference lists from inception to July 6, 2023, with an update to July 13, 2025. We included RCTs that compared specific analgesics with placebo or other analgesics administered after knee or hip arthroplasty. Studies were eligible if they enrolled at least 10 participants per arm, administered analgesics postoperatively, and reported outcomes related to pain, function, or adverse events. We excluded secondary analyses, abstracts only, and trials focused on chronic pain starting 2 months or more postoperatively. Of the 49,400 studies retrieved, a total of 47,465 were excluded after duplication and title and abstract screening, leaving 1935 articles for full-text review. From these, 211 eligible RCTs were included, comprising 22,972 patients (median [range] age 67 years [43 to 80 years]; female proportion 24% to 98%) and encompassing 155 distinct analgesic regimens across five administration routes (intravenous, nerve-block, local infiltration analgesia, oral, and topical) and their combinations. Risk of bias was assessed using the Cochrane Risk of Bias Tool 2.0 (79% were rated as having "some concerns" and 21% as "high risk"), and the confidence of the evidence was evaluated using The Confidence in Network Meta-Analysis framework, with ratings from moderate to very low. Pain was the primary outcome, with the focus on pain at 24 hours postoperatively; pain at 48 hours was included as a secondary outcome. We prioritized pain during movement over pain at rest, as it better reflects functional recovery. When studies reported multiple pain scales, data were extracted based on a predefined hierarchy: (1) VAS, (2) verbal rating scale, and (3) numeric rating scale. We prespecified a minimum clinically important difference (MCID) of -1.8 cm on a 10-cm VAS for pain, based on a previously published study. Function and adverse events were secondary outcomes. For data synthesis, we employed a Bayesian network meta-analysis model and used a random walk model to account for the temporal structure of pain outcomes. Heterogeneity was quantified using the between-trial variance (τ 2 ) and a random-effects model was applied, given the observed small to moderate heterogeneity. RESULTS: For pain management after knee arthroplasty, compared with placebo, local levobupivacaine was the most effective analgesic (mean difference -4.9 cm [95% credible interval (CrI) -7.5 to -2.2]; surface under the cumulative ranking [SUCRA] 99%), exceeding the prespecified MCID of -1.8 cm with an 85% probability. After hip arthroplasty, compared with placebo, local ropivacaine combined with ketorolac and adrenaline was most effective (mean difference -3.5 cm [95% CrI -4.9 to -2.0]; SUCRA 73%), with a 99% probability of achieving the MCID. For postoperative functional improvement after knee arthroplasty, compared with placebo, nerve-block levobupivacaine combined with dexmedetomidine (used under monitored conditions) showed the greatest benefit (mean difference 63° [95% CrI 35° to 91°]; SUCRA 88%), with a higher degree value meaning a greater ROM. Regarding safety, compared with placebo, intravenous tramadol combined with metoclopramide reduced the risk of nausea (OR 0.1 [95% CrI 0.0 to 0.7]), whereas nerve-block bupivacaine combined with sufentanil increased the risk (OR 6 [95% CrI 1 to 31]). No other differences were observed across interventions for the remaining adverse events. CONCLUSION: For knee arthroplasty, local levobupivacaine appeared to be the most effective option. For hip arthroplasty, local ropivacaine combined with ketorolac and adrenaline appeared the best. In terms of functional improvement, nerve-block levobupivacaine combined with dexmedetomidine (used under monitored conditions) appeared the most effective after knee arthroplasty. Although most interventions had similar safety profiles, intravenous tramadol combined with metoclopramide decreased the risk of nausea. Clinicians should integrate these results with known safety profiles and patient-specific factors to guide individualized postoperative pain management after knee and hip arthroplasties. LEVEL OF EVIDENCE: Level I, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. He H, Li C, Wen Z, et al. Which Analgesic Should We Use to Relieve Pain After Knee or Hip Arthroplasty? A Systematic Review and Network Meta-analysis of RCTs. Clin Orthop Relat Res. 2025. PMID: 41191391. doi:10.1097/CORR.0000000000003749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。